Matthew Solomon: Why Secondary Analyses of Clinical Trials Matter for Better Care
Matthew Solomon, Chief Scientific Officer at Sutter Health, shared a post on LinkedIn about a recent article by Harlan Krumholz and Harold Hines, published in JACC:
”Going through my stack of JACCs and this one really caught my eye
Kudos to the editorial team at the Journal of the American College of Cardiology for dedicating an entire issue to secondary analyses of clinical trials. It’s easy to focus only on primary endpoints, but there’s so much valuable learning in what comes next.
While some secondary results are hypothesis-generating, many offer critical clinical insights that help us understand nuances in treatment effects, patient subgroups, long-term outcomes, and underlying biology. Shining a spotlight on this work helps us translate trial evidence into better care.
Big thanks to the editors for the emphasis on this often under-appreciated yet essential part of clinical research.
What secondary analyses can do:
- Reveal effects in subpopulations that weren’t the focus of the primary endpoint
- Explore mechanistic insights or biological signals not captured by the primary outcome
- Extend follow-up to look at longer-term outcomes
- Refine endpoints or composite outcomes for future trials
- Test consistency of effects across methods or clinical contexts
These analyses help close gaps between trial results and real-world practice – and that’s why they matter.”
Title: When the Trial Is Over: What Secondary Analyses Still Teach Us
Authors: Harlan Krumholz, Harold Hines
Read the Full Article on Journal of the American College of Cardiology
Stay updated with Hemostasis Today.
-
Mar 24, 2026, 17:12Ron DePinho: CRISPR Progress in Cellular Immunotherapy
-
Mar 24, 2026, 17:12Martine Gilard։ Women’s Heart Health as a National Priority
-
Mar 24, 2026, 17:11Erik Nelson։ Blood Vessels – The Silent System That Determines How You Age
-
Mar 24, 2026, 17:10Anthony Yazbeck: Why the Hemolysin Test Matters More Than You Think
-
Mar 24, 2026, 17:09Marcos Gamboa Chele: Are We Asking for Too Many Thrombophilia Panels?
-
Mar 24, 2026, 17:06Anita Brikman: PPTA Explores India’s Growing Plasma-Derived Medicines Industry
-
Mar 24, 2026, 17:01Victor Canata: Is Embolectomy the Best Treatment for Pulmonary Thromboembolism?
-
Mar 24, 2026, 16:57Hossam Qassem: The Stepwise Investigation Framework for ICU Hemoglobin Drop
-
Mar 24, 2026, 16:56Alan Nurden: Targeting Splice Site Variants in Alport Syndrome with Antisense Therapy